A Phase 1 Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors
Status:
Not yet recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1 dose-escalation study of PRT3645, a Cyclin-dependent Kinase 4/6 (CDK4/6)
inhibitor, in patients with advanced or metastatic solid tumors. The purpose of this study is
to investigate the safety, tolerability, dose limiting toxicity, and to determine maximally
tolerated dose and recommended phase 2 dose to be used in subsequent development of PRT3645.